Temasek, Boyu Capital and others invest USD62m in D3 Bio Series A+
Source(s): Deal Street Asia
D3 Bio, a China-based clinical-stage biotech company backed by Temasek, raised a USD62m Series A+ led by Medicxi, with follow-on from Matrix Partners China and WuXi AppTec.